Just a single dose of psilocybin was safe and tolerable for adult women with anorexia, according to a phase I open-label feasibility study.
After receiving a 25-mg dose of synthetic psilocybin given with therapist-delivered psychological support, none of the 10 participants experienced any significant changes in vital signs, ECGs, or suicidality during the week after dosing, reported Stephanie Knatz Peck, PhD, of the University of California San Diego, and colleagues.
Meeting the primary outcome, the treatment was also well-tolerated, with no serious adverse events reported amongst participants, who had an average body mass index (BMI) of 19.7, they noted in Nature Medicine.
As for changes in psychopathology — the secondary outcome of the early-stage trial — concerns about weight significantly decreased from baseline to 1 month after psilocybin treatment.
This improvement was also maintained up to 3 months after dosing. Likewise, shape concerns significantly dropped within the month after treatment, but this change was no longer significant at the 3-month mark.
Changes in eating concerns and dietary restraint didn’t reach statistical significance, but there was a trend towards an improvement in eating concerns at the 3-month follow-up.
Hellbound and Down 